Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Phospholipase A2 (PLA2) enzymes are important toxins found in many snake venoms, and they can exhibit a variety of toxic activities including causing hemolysis and/or anticoagulation. In this study, the inhibiting effects of the small molecule PLA2 inhibitor varespladib on snake venom PLA2s was investigated by nanofractionation analytics, which combined chromatography, mass spectrometry (MS), and bioassays. The venoms of the medically important snake species Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, Daboia russelii, Echis carinatus, Echis ocellatus, and Oxyuranus scutellatus were separated by liquid chromatography (LC) followed by nanofractionation and interrogation of the fractions by a coagulation assay and a PLA2 assay. Next, we assessed the ability of varespladib to inhibit the activity of enzymatic PLA2s and the coagulopathic toxicities induced by fractionated snake venom toxins, and identified these bioactive venom toxins and those inhibited by varespladib by using parallel recorded LC-MS data and proteomics analysis. We demonstrated here that varespladib was not only capable of inhibiting the PLA2 activities of hemotoxic snake venoms, but can also effectively neutralize the coagulopathic toxicities (most profoundly anticoagulation) induced by venom toxins. While varespladib effectively inhibited PLA2 toxins responsible for anticoagulant effects, we also found some evidence that this inhibitory molecule can partially abrogate procoagulant venom effects caused by different toxin families. These findings further emphasize the potential clinical utility of varespladib in mitigating the toxic effects of certain snakebites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Superimposed PLA2 bioactivity chromatograms for nanofractionated venom toxins measured in the presence of the indicated concentrations of varespladib: (a) B. asper, (b) D. russelii, (c) E. carinatus, and (d) O. scutellatus. Top traces are the online LC-UV chromatograms recorded at 220, 254, and 280 nm for the respective venoms (allowing a correlation with LC-MS and proteomics data from Slagboom et al. [33]).](https://figures.cochat.ai/paper-figures/d384451edd094b588b107829b8b1ee80/varespladib-inhibits-the-phospholipase-a2-and-coagulopathic-activities-of-venom-figure-3.jpg)
![Figure 4 Coagulopathic toxicity chromatograms in the presence of various varespladib concentrations for nanofractionated venom toxins from (a) B. asper, (b) C. rhodostoma, (c) D. acutus, (d) D. russelii, (e) E. carinatus, (f) E. ocellatus, and (g) O. scutellatus. Top traces are the online LC-UV chromatograms recorded at 220, 254, and 280 nm for the respective venoms (allowing a correlation with LC-MS data and proteomics data from Slagboom et al. [33]).](https://figures.cochat.ai/paper-figures/d44c40bcb5aa4484be09c3124b7937cd/varespladib-inhibits-the-phospholipase-a2-and-coagulopathic-activities-of-venom-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Varespladib (LY315920) is a repurposed inhibitor of snake venom PLA2 [83,84,85,86] and is one of the most advanced adjunct therapeutics under investigation.”
From Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities (2026) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gutiérrez, J. M., Calvete, J. J., Habib, A. G., Harrison, R. A., Williams, D. J., & Warrell, D. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.63 · Cited by 955 · cited 1×
“Although snakebite envenoming is a severe medical problem that was recently added to the World Health Organization (WHO) list of Neglected Tropical Diseases [10], it has for a long time been systematically neglected by governments worldwide, despite over 100,000 people dying annually [11].”
BackgroundWilliams, D. J., Faiz, M. A., Abela-Ridder, B., Ainsworth, S., Bulfone, T. C., Nickerson, A. D., Habib, A. G., Junghanss, T., Fan, H. W., Turner, M., et al. (2019) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007059 · Cited by 447 · cited 2×
“Although snakebite envenoming is a severe medical problem that was recently added to the World Health Organization (WHO) list of Neglected Tropical Diseases [10], it has for a long time been systematically neglected by governments worldwide, despite over 100,000 people dying annually [11].”
BackgroundA model to explain the pharmacological effects of snake venom phospholipases A2
Kini, R. M., & Evans, H. J. (1989) · Toxicon · doi:10.1016/0041-0101(89)90013-5 · Cited by 411
Nicholls, S. J., Kastelein, J. J. P., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Koenig, W., Jukema, J. W., Nambi, V., et al. (2014) · JAMA · doi:10.1001/jama.2013.282836 · Cited by 344 · cited 1×
“Varespladib was originally found to reduce PLA2 concentrations in vivo, making it a candidate treatment for several cardiovascular diseases [17,21,22], including the treatment of acute coronary syndrome and systemic inflammatory response syndrome, but it was abandoned during Phase III clinical trials due to lack of ef…”
BackgroundCorrection: Snakebite envenoming
Gutiérrez, J. M., Calvete, J. J., Habib, A. G., Harrison, R. A., Williams, D. J., & Warrell, D. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.79 · Cited by 265
Lewin, M., Samuel, S., Merkel, J., & Bickler, P. (2016) · Toxins · doi:10.3390/toxins8090248 · Cited by 224
Ferraz, C. R., Arrahman, A., Xie, C., Casewell, N. R., Lewis, R. J., Kool, J., & Cardoso, F. C. (2019) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2019.00218 · Cited by 219
Self-citationThe paraspecific neutralisation of snake venom induced coagulopathy by antivenoms
Ainsworth, S., Slagboom, J., Alomran, N., Plá, D., Alhamdi, Y., King, S. I., Bolton, F. M. S., Gutiérrez, J. M., Vonk, F. J., Toh, C., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0039-1 · Cited by 117 · cited 1×
“Although current snakebite treatments, known as antivenoms (equine/ovine polyclonal antibodies), can be effective therapies capable of reducing morbidity and mortality, they have many limitations associated with them, leaving a critical therapeutic gap between snakebite and effective treatment [6,12].”
BackgroundSelf-citationAlbulescu, L.-O., Hale, M. S., Ainsworth, S., Alsolaiss, J., Crittenden, E., Calvete, J. J., Evans, C., Wilkinson, M. C., Harrison, R. A., Kool, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8314 · Cited by 111
Self-citationPhospholipases A2 from viperidae snake venoms: how do they induce skeletal muscle damage?
Lomonte, B., & Gutiérrez, J. M. (2011) · PubMed · Cited by 101
Cited by
Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings
Sokolova, M. V., Schett, G. A., & Steffen, U. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08890-1 · Cited by 166
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy
Subramaniyan, V., Chakravarthi, S., Jegasothy, R., Wu, Y. S., Fuloria, N. K., Fuloria, S., Hazarika, I., & Das, A. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.02.010 · Cited by 140
Gutiérrez, J. M., Albulescu, L.-O., Clare, R. H., Casewell, N. R., El‐Aziz, T. M. A., Escalante, T., & Rucavado, A. (2021) · Toxins · doi:10.3390/toxins13070451 · Cited by 103
Self-citationClinical management of snakebite envenoming: Future perspectives
Hamza, M., Knudsen, C., Gnanathasan, C. A., Monteiro, W. M., Lewin, M. R., Laustsen, A. H., & Habib, A. G. (2021) · Toxicon X · doi:10.1016/j.toxcx.2021.100079 · Cited by 104
Lewin, M. R., Carter, R. W., Matteo, I. A., Samuel, S. P., Rao, S., Fry, B. G., & Bickler, P. E. (2022) · Toxins · doi:10.3390/toxins14110783 · Cited by 94
“Recent observations have shown that the active pharmaceutical ingredient (API) varespladib (synonym LY315920) and its orally bioavailable methyl ester prodrug, varespladib-methyl (synonym LY333013), possess potent inhibitory activity against dozens of venom sPLA2s, with IC50 values ranging from picoto nanomolar concen…”
BackgroundInfluential
Metadata
- Authors
- Xie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J.
- Affiliations
- Vrije Universiteit Amsterdam (NL)
- Liverpool School of Tropical Medicine (GB)
- Institute of Pharmaceutical Analysis, College of Pharmacy, Jinan University, Huangpu Avenue West 601, Guangzhou 510632, China
- Jinan University (CN)
- Naturalis Biodiversity Center (NL)
- Corresponding author
- Kool, Jeroen
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2020-06-17
- Volume
- 8
- Issue
- 6
- Pages
- 165
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC7345350
- OpenAlex
- W3036003840
- Cited by
- 58
- References
- 39
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 5 · 2023: 5 · 2022: 13 · 2021: 24 · 2020: 4
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- China Scholarship Council (CSC) fellowship (201706250035)
- UK Medical Research Council (MRC) Research Grant (MR/S00016X/1)
- Confidence in Concept Award (CiC19017)
- Sir Henry Dale Fellowship (200517/Z/16/Z)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Venomous Animal Envenomation and Studies
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Amphibian and Reptile Biology
- Health Sciences › Medicine › Pharmacology (medical) › Healthcare and Venom Research
- Keywords
- varespladib, phospholipase A2, snake venom, anticoagulant activity, procoagulant activity, snakebite, Bothrops asper, Calloselasma rhodostoma, Deinagkistrodon acutus, Daboia russelii, Echis carinatus, Echis ocellatus, Oxyuranus scutellatus, venom proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes. https://app.cochat.ai/papers/10.3390/biomedicines8060165
- The paper
- Xie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020). Varespladib Inhibits the Phospholipase A2 and Coagulopathic Activities of Venom Components from Hemotoxic Snakes. Biomedicines. https://doi.org/10.3390/biomedicines8060165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.